title: T cell receptor excision circle (TREC) content following maximum HIV suppression is equivalent in HIV-infected and HIV-uninfected individuals.
abstract: BACKGROUND
  The adult human thymus contributes to de novo T cell synthesis; such synthesis can be assessed by analyzing T cell receptor excision circles (TREC).
  
  
  METHODS
  TREC levels were measured in total peripheral blood mononuclear cells (PBMC) and CD4- and CD8-enriched cells of 29 HIV-positive patients with maximal viral suppression. The expression of CD45RA+CD45RO-, CD45RA+CD62L+, CD45RO-CD27+CD95low and HLA-DR+CD38+ was assessed using three-color flow cytometric analysis of whole blood. Thymic index score was based on computed tomographic scans of the thymus. The relationship of TREC with thymic index and the expression of the naive phenotypes was evaluated.
  
  
  RESULTS
  TREC expression was not statistically different in these HIV-positive patients from that in age-matched HIV-negative controls. Among HIV-positive patients with CD4 cell count of > 500 x 10(6) cells/l after antiretroviral therapy (n = 15), PBMC TREC levels correlated with the expression of CD45RA+CD45RO- and CD45RA+CD62L+ naive phenotypes, and inversely correlated with the expression of HLA-DR+CD38+. The change between pre- and post-therapy CD4 cell counts for these 15 patients significantly correlated with both thymic index and expression of the CD45RA+CD45RO- phenotype.
  
  
  CONCLUSIONS
  The finding that TREC expression was equivalent between HIV-positive patients after therapy and HIV-negative donors suggests that there is no reduction in thymic output among HIV-positive individuals after therapy. Given that TREC is inversely correlated with HLA-DR/CD38 expression, its analysis in studies of thymopoiesis should be evaluated in the context of maximum viral suppression to reduce HIV-mediated immune activation and/or by normalizing for cell turnover.
authors.affiliation: Department of Immunology/Microbiology, Rush-Presbyterian-St Luke's Medical Center, Chicago, Illinois 60612, USA.
authors.forename: C M
authors.initials: CM
authors.lastname: Steffens
authors.forename: K Y
authors.initials: KY
authors.lastname: Smith
authors.forename: A
authors.initials: A
authors.lastname: Landay
authors.forename: S
authors.initials: S
authors.lastname: Shott
authors.forename: A
authors.initials: A
authors.lastname: Truckenbrod
authors.forename: M
authors.initials: M
authors.lastname: Russert
authors.forename: L
authors.initials: L
authors.lastname: Al-Harthi
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D005260:Female; D015329:Gene Rearrangement, T-Lymphocyte / Q000235:genetics*; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology* / Q000821:virology; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000276:immunology / Q000378:metabolism*; D008297:Male; D011948:Receptors, Antigen, T-Cell / Q000097:blood*; D013950:Thymus Gland / Q000502:physiology*; D019562:Viral Load
chemical_list: D011948:Receptors, Antigen, T-Cell